Company: NCEL
Filing Date: 2025-02-10
Form Type: 425
Source: 0001213900-25-011502
Chunk: 3

Company: NewcelX Ltd.
Filing Date: 2025-02-10
Form: 425
Chunk 3
---
 cell therapy and NLS’s leadership in pharmaceutical innovation. This strategic integration is expected
to strengthen their position in the diabetes treatment landscape, offering a differentiated approach that combines regenerative
medicine with novel pharmaceutical interventions.

By leveraging synergies in neurodegenerative
and metabolic disease research, the combined entity aims to position itself to drive innovation in diabetes and beyond, establishing
itself as a key player in the evolving therapeutic space.

<div align='center'>2</div>

A New Era in Diabetes Treatment

While GLP-1 receptor agonists will continue
to play a role in diabetes care, we do not believe that they alone cannot fully address the neurological and systemic complications
of diabetes. The DOXA multi-target strategy presents a transformative, complementary approach, is aimed at tackling not
just glucose regulation, but also neuroprotection, metabolic resilience, and long-term disease modification. As diabetes research
advances, multi-target therapies are set to redefine the next generation of diabetes treatments. By integrating breakthroughs
in sleep-wake regulation, neuroprotection, and metabolic health, NLS is aiming to pioneer a new era of diabetes care—one that
offers comprehensive, long-lasting benefits for patients and new investment opportunities for the future.

Dr Eric Konofal, M.D., PhD, Chief Scientific Officer of NLS and inventor behind DOXA: “I believe that this next-generation diabetes treatment must go beyond glucose control. While GLP-1 therapies address part of the problem, they fail to target the neurological and systemic disruptions linked to the disease, including Diabetes-Associated Neurological and Sleep Disorders (DANS). At NLS, our DOXA platform aims to integrate neuroscience, metabolism, and regenerative medicine. Combined with Islet transplantation, we anticipate a breakthrough—enhancing insulin sensitivity, metabolic regulation, and long-term disease modification.”

Alex Zwyer, Chief Executive Officer of NLS,
“This planned merger represents a remarkable opportunity to combine our strengths and expertise. Together, believe that we will advance innovative solutions to better address the challenges of diabetes and related disorders, delivering enhanced value to patients.”

Ronen Twito, Executive Chairman and Chief Executive Officer of Kadimastem, added, “We are thrilled about the upcoming merger, which aligns our strategic goals and is aimed at empowering us to provide comprehensive therapeutic options. By joining forces, we believe that we will be well-equipped to tackle the complexities of diabetes and improve outcomes for those we serve.”

<div align='center'>3</div>

The upcoming merger reflects a commitment to innovation